Biogen lays out three FDA decisions that could ramp up Alzheimer's drug launch
Since its approval in 2023, the Alzheimer's disease drug made by Biogen Inc. and Eisai has seen a lackluster launch. However, Biogen CEO Chris Viehbacher said on Tuesday that there are a “number of ...
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1)
Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...
The Pharma Letter2d
BRIEF—Biogen sued by Sage after buyout offer
US biotech Sage Therapeutics on Friday sued Biogen, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million, according to a ...
Seeking Alpha3d
Sage sues Biogen in wake of $469M buyout offer: report
Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the wake of an unsolicited takeover bid valued at around $469M. The full ...
pharmaphorum4d
Biogen gets much-needed pipeline lift with speedy ALS drug review
With Biogen squeezed between competitive pressures to its current multiple sclerosis and spinal muscular atrophy products and almost zero sales of Aduhelm, a lot is riding on its Alzheimer's ...
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal
Humana Inc. fell short of pleading standards in its racketeering lawsuit against Biogen Inc. over its allegedly fraudulent ...
Benzinga.com18d
17 Analysts Assess Biogen: What You Need To Know
Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and ...
FiercePharma3d
Analysts tip Eisai, Biogen and Lilly to drive eightfold explosion in Alzheimer's market value
GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...
FiercePharma8d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
Biogen has offered to purchase Sage’s outstanding shares for $7.22 each, according to a securities filing from Friday. The proposal values Sage at around $442 million. A yearslong partner of ...
Business Insider4d
Biogen (BIIB) Receives a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target of $138.00. The company’s shares closed yesterday ...
Yahoo Finance19d
Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges
Biogen is in a difficult balancing act “with ... Piper Sandler flagged several headwinds for MS products, including competition from biosimilars and upcoming loss of exclusivity for key drugs ...
Seeking Alpha6d
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Sage Therapeutics, Inc. (NASDAQ:SAGE) recently received an unsolicited bid proposal from Biogen Inc. (BIIB) to be purchased at around $7.22 per share. This represents a 30% premium to the price of ...